EE Impact

Zentiva

Czech Republic · Pharma & Healthcare

LeaveRussia detail: Continue Operations

Still operating in Russia

Zentiva is a pharmaceutical company based in Prague, Czech Republic. The company is developing, manufacturing and marketing a wide range of generic and OTC products. Zentiva employs more than 4 700 people across Europe and has three manufacturing sites, in Prague, Bucharest and Ankleshwar.

Status last verified 03/08/2026Source checked 10/06/2025Company website ↗LeaveRussia profile ↗

Decision trail

Decision date 28/03/2025 · Reference ↗

Received revenues in Russia in 2022-2024. Zentiva sells operations in Russia and CIS markets, no details disclosed officially so far. Revenue increased in 2024 vs 2023 by more than +30%.

Local stats (LeaveRussia)

Assets(RF), mln.USD
47
Capital(RF), mln.USD
17
Revenue(RF), mln.USD
89
Staff(RF), 2021
173
Taxes(RF), mln.USD
3
Glob.Revenue, mln.USD
50261

Status history since 2022

  1. 03/08/2026 operating · Imported from KSE LeaveRussia

Exposure profile

Full exposure profile is a Professional feature

Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.

Upgrade to Professional
Statuses, logos and narrative notes are compiled from public reporting and the KSE LeaveRussia project. Found an error? See our corrections policy.